Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?

Hans W M Niessen, Paul A J Krijnen, Cees A Visser, Chris J L M Meijer, C Erik Hack

Research output: Contribution to journalReview articleAcademicpeer-review

56 Citations (Scopus)


Inflammatory reactions contribute to the pathogenesis of cardiovascular conditions such as atherosclerosis and ischemic damage in acute myocardial infarction (AMI). Among the mediators involved in inflammation are secretory phospholipase A2 group II (sPLA2-II) enzymes. Though some cells constitutively express sPLA2-II, the synthesis by cells such as hepatocytes is typical for an acute-phase reactant. Recent literature suggests multiple roles for sPLA2-II in cardiovascular disease. In this review we discuss the role of sPLA2-II in various in vivo and in vitro models of atherosclerosis or AMI, including the therapeutic perspective of sPLA2-II inhibitors. It was concluded that sPLA2-II appears to be an important inflammatory mediator of cardiovascular disease.

Original languageEnglish
Pages (from-to)68-77
Number of pages10
JournalCardiovascular research
Issue number1
Publication statusPublished - 15 Oct 2003


  • Arteriosclerosis
  • Endothelial Cells
  • Endothelium, Vascular
  • Enzyme Inhibitors
  • Group II Phospholipases A2
  • Humans
  • Journal Article
  • Lipoproteins
  • Macrophages
  • Myocardial Ischemia
  • Myocytes, Cardiac
  • Oligonucleotides, Antisense
  • Phospholipases A
  • Phospholipases A2
  • Research Support, Non-U.S. Gov't
  • Review

Cite this